EC clears $17 billion acquisition of Hospira by Pfizer

EC clears $17 billion acquisition of Hospira by Pfizer

Raphaël De Coninck, Roman Fischer, Mikaël Hervé
Antitrust & Competition | European competition

The European Commission has cleared the acquisition of Hospira by Pfizer in phase 1. The clearance is subject to the divestment of some sterile injectable drugs and one biosimilar pipeline.

A CRA team led by Raphaël De Coninck and including Elina Koustoumpardi, Roman Fischer, and Mikaël Hervé advised and provided economic support to Pfizer during the pre-notification and phase 1 proceedings in front of the European Commission.

For more details, please see the Commission's press release.